Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis prostate cancer drug trial meets primary endpoint By: MarketWatch December 05, 2022 at 01:44 AM EST The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said. Read More >> Related Stocks: Novartis Ag ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Novartis prostate cancer drug trial meets primary endpoint By: MarketWatch December 05, 2022 at 01:44 AM EST The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said. Read More >> Related Stocks: Novartis Ag ADR